Is the Global Defense Boom Fuelling Investments in Aerospace and Defense ETFs?

Global defense spending soared 9.4% year-over-year to USD 2.7 trillion in 2024, driven by geopolitical tensions and technological modernization across regions like Europe and the Middle East, according to the Stockholm International Peace Research Institute (SIPRI). With defense budgets projected to reach USD 3.6 …

Aditi Sarkar | 16 Jul 2025| Read Time : 10 Mins

Hansen Technologies Gains Buy Ratings as Analysts See Up to 31% Upside Following FY25 EBITDA Upgrade

Shaw and Partners reiterates BUY rating with a price target of AUD 7.30, implying a 31.29% upside.

Sonal Goyal | 16 Jul 2025| Read Time : 10 Mins

ASX: IMU, IMR and NEM Shares Slide Amid Broader Market Weakness

In Wednesday afternoon trade, the S&P/ASX 200 Index was tracking lower, down 0.9% to 8,555.5 points, as declines in healthcare and resources weighed on overall market sentiment. Several individual stocks posted notable losses, including Imugene Ltd, Imricor Medical Systems Inc, and Newmont Corporation.

Team Kalkine | 16 Jul 2025| Read Time : 10 Mins

ASX: DRO, MEI and MGX Shares Rise Amid Index Decline

While the S&P/ASX 200 Index traded 0.75% lower at 8,565.8 points on Wednesday, select small- and mid-cap stocks outperformed, with DroneShield Ltd, Meteoric Resources NL, and Mount Gibson Iron Ltd among notable gainers on the day.

Team Kalkine | 16 Jul 2025| Read Time : 10 Mins

Saunders (ASX: SND) to Acquire Aqua Metro in AUD 30M Water Sector Expansion Move

Saunders International Limited (ASX:SND)has announced a Share Sale Agreement to acquire 100% of Aqua Metro Pty Ltd and its associated entities in a transaction valued at up to AUD 30.0 million. The deal is expected to complete in the first quarter of FY26, subject …

Team Kalkine | 16 Jul 2025| Read Time : 10 Mins

Ora Banda Mining Receives Multiple Buy Ratings as Analysts See Over 50% Upside

Canaccord Genuity assigns a BUY rating with a 54.41% price upside, targeting AUD 1.05.

Sonal Goyal | 16 Jul 2025| Read Time : 10 Mins

Noxopharm (ASX: NOX) Administers First Dose in HERACLES Autoimmune Drug Trial

Noxopharm Limited (ASX:NOX), a clinical-stage biotechnology company, has initiated dosing in its first-in-human HERACLES clinical trial, marking the initial human application of SOF-SKN™, a topical drug candidate designed to address autoimmune diseases. The trial represents the first clinical step for the company’s proprietary Sofra™ …

Team Kalkine | 16 Jul 2025| Read Time : 10 Mins

News

Is the Global Defense Boom Fuelling Investments in Aerospace and Defense ETFs?

Hansen Technologies Gains Buy Ratings as Analysts See Up to 31% Upside Following FY25 EBITDA Upgrade

ASX: IMU, IMR and NEM Shares Slide Amid Broader Market Weakness

ASX: DRO, MEI and MGX Shares Rise Amid Index Decline

Saunders (ASX: SND) to Acquire Aqua Metro in AUD 30M Water Sector Expansion Move

Ora Banda Mining Receives Multiple Buy Ratings as Analysts See Over 50% Upside

Noxopharm (ASX: NOX) Administers First Dose in HERACLES Autoimmune Drug Trial

Premium News

Is the Global Defense Boom Fuelling Investments in Aerospace and Defense ETFs?

U.S. Aerospace and Defense ETFs Rise on Sector Tailwinds and Diverse Index Strategies

Cleanaway (ASX:CWY) Gains ACCC Approval, Guides for Double-Digit EBIT Growth in FY25

Amplia Therapeutics (ASX:ATX) Share Price Up 442% in a Month, Despite AUD 6.57Mn Losses in FY25

Eureka Group (ASX:EGH) Targets Asset Divestments and Acquisitions to Drive FY25 Growth

AMA Group (ASX:AMA) EBITDA Doubles in Q3FY25, Projects EBITDA of AUD 58-62Mn in FY25

PYC Therapeutics (ASX:PYC) Boosts Pipeline with Promising Trials and Nearly Doubled Cash Reserves in H1FY25